Allarity Therapeutics enters $947,000 at-the-market equity offering agreement with Ascendiant Capital

Allarity Therapeutics, Inc.

Company entered ATM sales agreement with Ascendiant Capital for up to $947,000 of common stock.
Agent commission 3.0% of gross proceeds; expenses reimbursement up to $30,000.
Sales may be made on Nasdaq at market prices; agreement effective until March 2026 or earlier termination.
Placement Shares subject to General Instruction I.B.6 limitations until public float exceeds $75M.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Allarity Therapeutics, Inc. entered into At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC valued at up to $947,000 (effective 2024-03-19).

Action: entry
Agreement: atm program
Counterparty: Ascendiant Capital Markets, LLC
Value: up to $947,000
Effective: 2024-03-19

Exact text from the filing

On March 19, 2024, Allarity Therapeutics, Inc. (the “ Company ”), entered into an At-The-Market Issuance Sales Agreement (the “ Agreement ”) with Ascendiant Capital Markets, LLC (the “ Agent ”), pursuant to which the Company may offer and sell, from time to time, through the Agent, shares

View on SEC.gov

547 material agreements filed in the last 30 days. Browse all material agreements →

Allarity Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-024156

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.